BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 34313552)

  • 1. Highly sensitive detection of antibody nonspecific interactions using flow cytometry.
    Makowski EK; Wu L; Desai AA; Tessier PM
    MAbs; 2021; 13(1):1951426. PubMed ID: 34313552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toward Drug-Like Multispecific Antibodies by Design.
    Sawant MS; Streu CN; Wu L; Tessier PM
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33053650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction of therapeutic antibody self-association using yeast-display selections and machine learning.
    Makowski EK; Chen H; Lambert M; Bennett EM; Eschmann NS; Zhang Y; Zupancic JM; Desai AA; Smith MD; Lou W; Fernando A; Tully T; Gallo CJ; Lin L; Tessier PM
    MAbs; 2022; 14(1):2146629. PubMed ID: 36433737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Addressing polyspecificity of antibodies selected from an in vitro yeast presentation system: a FACS-based, high-throughput selection and analytical tool.
    Xu Y; Roach W; Sun T; Jain T; Prinz B; Yu TY; Torrey J; Thomas J; Bobrowicz P; Vásquez M; Wittrup KD; Krauland E
    Protein Eng Des Sel; 2013 Oct; 26(10):663-70. PubMed ID: 24046438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bispecific antibody target pair discovery by high-throughput phenotypic screening using in vitro combinatorial Fab libraries.
    Bhatta P; Whale KD; Sawtell AK; Thompson CL; Rapecki SE; Cook DA; Twomey BM; Mennecozzi M; Starkie LE; Barry EMC; Peters SJ; Kamal AM; Finney HM
    MAbs; 2021; 13(1):1859049. PubMed ID: 33487120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improving biophysical properties of a bispecific antibody scaffold to aid developability: quality by molecular design.
    Von Kreudenstein TS; Escobar-Carbrera E; Lario PI; D'Angelo I; Brault K; Kelly J; Durocher Y; Baardsnes J; Woods RJ; Xie MH; Girod PA; Suits MD; Boulanger MJ; Poon DK; Ng GY; Dixit SB
    MAbs; 2013; 5(5):646-54. PubMed ID: 23924797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel efficient bispecific antibody format, combining a conventional antigen-binding fragment with a single domain antibody, avoids potential heavy-light chain mis-pairing.
    Huang S; Segués A; Hulsik DL; Zaiss DM; Sijts AJAM; van Duijnhoven SMJ; van Elsas A
    J Immunol Methods; 2020 Aug; 483():112811. PubMed ID: 32569598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
    Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I
    MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tethered-variable CL bispecific IgG: an antibody platform for rapid bispecific antibody screening.
    Kim HS; Dunshee DR; Yee A; Tong RK; Kim I; Farahi F; Hongo JA; Ernst JA; Sonoda J; Spiess C
    Protein Eng Des Sel; 2017 Sep; 30(9):627-637. PubMed ID: 28985411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid optimization and prototyping for therapeutic antibody-like molecules.
    Xu L; Kohli N; Rennard R; Jiao Y; Razlog M; Zhang K; Baum J; Johnson B; Tang J; Schoeberl B; Fitzgerald J; Nielsen U; Lugovskoy AA
    MAbs; 2013; 5(2):237-54. PubMed ID: 23392215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type I (IGF-1R) demonstrating unique molecular properties.
    Schanzer JM; Wartha K; Croasdale R; Moser S; Künkele KP; Ries C; Scheuer W; Duerr H; Pompiati S; Pollman J; Stracke J; Lau W; Ries S; Brinkmann U; Klein C; Umana P
    J Biol Chem; 2014 Jul; 289(27):18693-706. PubMed ID: 24841203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid identification of highly potent human anti-GPCR antagonist monoclonal antibodies.
    Scott MJ; Jowett A; Orecchia M; Ertl P; Ouro-Gnao L; Ticehurst J; Gower D; Yates J; Poulton K; Harris C; Mullin MJ; Smith KJ; Lewis AP; Barton N; Washburn ML; de Wildt R
    MAbs; 2020; 12(1):1755069. PubMed ID: 32343620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new approach for generating bispecific antibodies based on a common light chain format and the stable architecture of human immunoglobulin G
    De Nardis C; Hendriks LJA; Poirier E; Arvinte T; Gros P; Bakker ABH; de Kruif J
    J Biol Chem; 2017 Sep; 292(35):14706-14717. PubMed ID: 28655766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair.
    Strop P; Ho WH; Boustany LM; Abdiche YN; Lindquist KC; Farias SE; Rickert M; Appah CT; Pascua E; Radcliffe T; Sutton J; Chaparro-Riggers J; Chen W; Casas MG; Chin SM; Wong OK; Liu SH; Vergara G; Shelton D; Rajpal A; Pons J
    J Mol Biol; 2012 Jul; 420(3):204-19. PubMed ID: 22543237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fucose removal from complex-type oligosaccharide enhances the antibody-dependent cellular cytotoxicity of single-gene-encoded bispecific antibody comprising of two single-chain antibodies linked to the antibody constant region.
    Natsume A; Wakitani M; Yamane-Ohnuki N; Shoji-Hosaka E; Niwa R; Uchida K; Satoh M; Shitara K
    J Biochem; 2006 Sep; 140(3):359-68. PubMed ID: 16861252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. "BIClonals": Production of Bispecific Antibodies in IgG Format in Transiently Transfected Mammalian Cells.
    Litvak-Greenfeld D; Vaks L; Dror S; Nahary L; Benhar I
    Methods Mol Biol; 2019; 1904():431-454. PubMed ID: 30539485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Full-length recombinant antibodies from
    Rashid MH
    MAbs; 2022; 14(1):2111748. PubMed ID: 36018829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Understanding the role of cross-arm binding efficiency in the activity of monoclonal and multispecific therapeutic antibodies.
    Harms BD; Kearns JD; Iadevaia S; Lugovskoy AA
    Methods; 2014 Jan; 65(1):95-104. PubMed ID: 23872324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Highly effective recombinant format of a humanized IgG-like bispecific antibody for cancer immunotherapy with retargeting of lymphocytes to tumor cells.
    Asano R; Watanabe Y; Kawaguchi H; Fukazawa H; Nakanishi T; Umetsu M; Hayashi H; Katayose Y; Unno M; Kudo T; Kumagai I
    J Biol Chem; 2007 Sep; 282(38):27659-65. PubMed ID: 17644522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DuoMab: a novel CrossMab-based IgG-derived antibody format for enhanced antibody-dependent cell-mediated cytotoxicity.
    Sustmann C; Dickopf S; Regula JT; Kettenberger H; Mølhøj M; Gassner C; Weininger D; Fenn S; Manigold T; Kling L; Künkele KP; Schwaiger M; Bossenmaier B; Griese JJ; Hopfner KP; Graff-Meyer A; Stahlberg H; Ringler P; Lauer ME; Brinkmann U; Schaefer W; Klein C
    MAbs; 2019; 11(8):1402-1414. PubMed ID: 31526159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.